All Oncology News

Florida Cancer Specialists & Research Institute Opens New State-of-the-Art Cancer Center in North Port

October 26th 2021

Florida Cancer Specialists & Research Institute has opened its new state-of-the-art North Port Cancer Center, providing the most advanced and personalized treatments and services for patients with all forms of cancers and blood disorders.

A New Era of Precision Medicine Takes Shape in Prostate Cancer

October 26th 2021

Christina Loguidice

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

Scope of Treatment Sequencing Grows in Genitourinary Malignancies

October 26th 2021

Caroline Seymour

Jonathan A. Chatzkel, MD, discusses updates in first-line treatment options for metastatic urothelial cancer, as well as recommended treatments for patients with previously treated, locally advanced or metastatic urothelial cancer, and also newly diagnosed metastatic renal cell carcinoma.

Toxicity Management Remains Key With Expanding Frontline Treatment Options in Lung Cancer

October 25th 2021

Jessica Hergert

Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.

FDA Grants Fast Track Status to Cancer Vaccine UV1 for Advanced Malignant Melanoma

October 25th 2021

Kristi Rosa

The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab or to ipilimumab.

Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC

October 25th 2021

OncLive Staff

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

Eryaspase/Chemo Misses OS End Point in Second-Line Pancreatic Cancer, But Warrants Further Investigation

October 25th 2021

Kristi Rosa

Although the addition of eryaspase to chemotherapy improved overall survival over chemotherapy alone in patients with metastatic pancreatic cancer, the difference in benefit was not found to be statistically significant, missing the primary end point of the phase 3 TRYbeCA-1 trial.

Durvalumab Plus Chemo Significantly Improves OS in Frontline Advanced Biliary Tract Cancer

October 25th 2021

Kristi Rosa

The combination of durvalumab and chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone when used in the first-line treatment of patients with advanced biliary tract cancer, meeting the primary end point of the phase 3 TOPAZ-1 trial.

Risk-Stratification Can Be Used to Prevent Overtreatment in Children, AYA Patients With Synovial Sarcoma

October 25th 2021

Gina Mauro

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

Canakinumab Combo Misses Survival End Points in Previously Untreated Locally Advanced or Metastatic NSCLC

October 25th 2021

Kristi Rosa

Canakinumab plus pembrolizumab and platinum-based doublet chemotherapy did not significantly improve progression-free survival or overall survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer, missing the primary end points of the phase 3 CANOPY-1 trial.

Association of Community Cancer Centers Announces Annual Innovator Award Winners

October 25th 2021

The Association of Community Cancer Centers (ACCC) today announced the winning programs for its eleventh annual ACCC Innovator Awards, spotlighting forward-thinking cancer care programs tackling challenges ranging from financial toxicity to telehealth advancements.

The Challenging Future of the FDA in the Cancer Arena

October 25th 2021

Maurie Markman, MD

Maurie Markman, MD, highlights the ongoing regulatory concerns that demand attention of the FDA in the cancer arena amidst evolving issues regarding COVID-19.

Updates in HER2+ Breast Cancer from ESMO 2021

October 25th 2021

Joyce A. O'Shaughnessy

Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.

Children With Cancer At Higher Risk for Severe Illness from COVID-19

October 24th 2021

Courtney Marabella

Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness and deaths due to the infection were proportionally higher in this patient population compared with the general pediatric population, providing evidence that children with cancer are at higher risk of developing severe illness from COVID-19.

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing

October 23rd 2021

Jessica Bauman, MD, Fox Chase Cancer Center

The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.